Magdalena Kegel,  —

Acadia Pharmaceuticals reports that pimavanserin was particularly effective in treating psychosis in Alzheimer’s disease patients who had severe psychotic symptoms, without triggering a deterioration in their cognition. The information, which stems from additional analyses of data gathered in a Phase 2 trial of pimavanserin in Alzheimer’s patients, was…

Researchers may have discovered the reason certain investigational therapies failed in Alzheimer’s disease clinical trials — a finding that could lead to new trials with a greater chance of success, according to a study published in the journal Cell Reports. A class of drugs, intended to block an enzyme…

The Alzheimer’s disease community has grown accustomed to news of an endless string of failures in clinical trials of potential treatments. In fact, only four such treatments went on to win approval between 1998 and 2014 — addressing symptoms but not altering the relentless course of the disease. PhRMA…

A list of more than 80 compounds in clinical trials for Alzheimer’s disease, released by PhRMA, inevitably brings to mind all those that failed previously. But researchers view the new list as a source of hope, increasingly confident a breakthrough may be among them. Alzheimer’s News Today spoke…

In a discovery that might provide an entirely new angle to Alzheimer’s disease research, scientists have mapped lymphatic vessels to the outside of the brains of living humans. Because these vessels are the main route traveled by immune cells, the finding, described in the journal eLife, may allow scientists…

Clumps of the Alzheimer’s-related protein amyloid-beta in nerves around organs related to smell may explain why people in the early stages of the disease lose their ability to detect odors, a study reports. Researchers at the Daegu Gyeungbuk Institute of Science and Technology in South Korea also discovered that loss…

Certain personality traits — like high levels of neuroticism and low conscientiousness — may be linked to a higher risk of Alzheimer’s disease and other forms of dementia, finds a study published in the journal JAMA Psychiatry. But people don’t develop these traits are during pre-symptomatic stages of the disease,…

AgeneBio has obtained a National Institute on Aging grant to conduct a Phase 3 clinical trial of AGB101 (levetiracetam), a compound intended to prevent people with mild memory impairment from developing Alzheimer’s disease. The agency, part of the National Institutes of Health (NIH), has been backing the potential therapy’s development for…

Research on Alzheimer’s treatments could benefit from the adaptive clinical trial approach used in breast cancer research, three Georgetown University scientists argue in a commentary. An adaptive approach involves modifying a trial as results come in to find the best way to treat the disease the trial is examining. The…

A new type of analysis allowed researchers to use a blood test to help to identify patients with Alzheimer’s in a group of people with neurodegenerative diseases, a study published in the journal PNAS reports. The test showed far better accuracy than earlier attempts at sampling blood to detect…